{"id":32007,"date":"2025-04-18T13:35:13","date_gmt":"2025-04-18T05:35:13","guid":{"rendered":"https:\/\/flcube.com\/?p=32007"},"modified":"2025-04-18T13:35:14","modified_gmt":"2025-04-18T05:35:14","slug":"gsks-blenrep-approved-by-uk-mhra-for-multiple-myeloma-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32007","title":{"rendered":"GSK’s Blenrep Approved by UK MHRA for Multiple Myeloma Treatment"},"content":{"rendered":"\n

UK-based pharmaceutical giant UK-based pharmaceutical company GlaxoSmithKline (GSK, NYSE: GSK<\/a>)\u00a0 has announced the receipt of marketing approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin). The approval allows Blenrep to be used in combination with bortezomib plus dexamethasone (BVd) for adults with multiple myeloma (MM) who have received at least one prior therapy, and with pomalidomide plus dexamethasone (BPd) for patients who have received at least one prior therapy including lenalidomide. This marks the first global approval for Blenrep in these specific treatment settings.<\/p>\n\n\n\n

Clinical Trial Evidence<\/strong>
The MHRA\u2019s decision is supported by data from the pivotal DREAMM-7 and DREAMM-8 Phase III trials. These trials demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) for Blenrep combinations compared to standard triplet therapies in the second-line or later treatment of MM. The results highlight Blenrep\u2019s potential to enhance treatment outcomes for patients with relapsed or refractory multiple myeloma.<\/p>\n\n\n\n

Blenrep\u2019s Mechanism and Technology<\/strong>
Blenrep is an ADC consisting of a humanized BCMA monoclonal antibody linked to the cytotoxic agent auristatin F via a non-cleavable linker. The drug\u2019s linker technology is licensed from Seagen Inc., and the monoclonal antibody is produced using POTELLIGENT Technology licensed from BioWa Inc., a member of the Kyowa Kirin Group. This innovative technology enables targeted delivery of chemotherapy to cancer cells, minimizing systemic toxicity.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

UK-based pharmaceutical giant UK-based pharmaceutical company GlaxoSmithKline (GSK, NYSE: GSK)\u00a0 has announced the receipt of…<\/p>\n","protected":false},"author":1,"featured_media":32008,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,278,184,914,15],"class_list":["post-32007","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk","tag-product-approvals"],"yoast_head":"\nGSK's Blenrep Approved by UK MHRA for Multiple Myeloma Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based pharmaceutical giant UK-based pharmaceutical company GlaxoSmithKline (GSK, NYSE: GSK)\u00a0 has announced the receipt of marketing approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin). The approval allows Blenrep to be used in combination with bortezomib plus dexamethasone (BVd) for adults with multiple myeloma (MM) who have received at least one prior therapy, and with pomalidomide plus dexamethasone (BPd) for patients who have received at least one prior therapy including lenalidomide. This marks the first global approval for Blenrep in these specific treatment settings.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32007\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK's Blenrep Approved by UK MHRA for Multiple Myeloma Treatment\" \/>\n<meta property=\"og:description\" content=\"UK-based pharmaceutical giant UK-based pharmaceutical company GlaxoSmithKline (GSK, NYSE: GSK)\u00a0 has announced the receipt of marketing approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin). The approval allows Blenrep to be used in combination with bortezomib plus dexamethasone (BVd) for adults with multiple myeloma (MM) who have received at least one prior therapy, and with pomalidomide plus dexamethasone (BPd) for patients who have received at least one prior therapy including lenalidomide. This marks the first global approval for Blenrep in these specific treatment settings.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32007\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-18T05:35:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-18T05:35:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1803.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32007#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32007\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK’s Blenrep Approved by UK MHRA for Multiple Myeloma Treatment\",\"datePublished\":\"2025-04-18T05:35:13+00:00\",\"dateModified\":\"2025-04-18T05:35:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32007\"},\"wordCount\":248,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32007#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1803.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32007#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32007\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32007\",\"name\":\"GSK's Blenrep Approved by UK MHRA for Multiple Myeloma Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32007#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32007#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1803.webp\",\"datePublished\":\"2025-04-18T05:35:13+00:00\",\"dateModified\":\"2025-04-18T05:35:14+00:00\",\"description\":\"UK-based pharmaceutical giant UK-based pharmaceutical company GlaxoSmithKline (GSK, NYSE: GSK)\u00a0 has announced the receipt of marketing approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin). The approval allows Blenrep to be used in combination with bortezomib plus dexamethasone (BVd) for adults with multiple myeloma (MM) who have received at least one prior therapy, and with pomalidomide plus dexamethasone (BPd) for patients who have received at least one prior therapy including lenalidomide. This marks the first global approval for Blenrep in these specific treatment settings.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32007#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32007\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32007#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1803.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1803.webp\",\"width\":1080,\"height\":608,\"caption\":\"GSK's Blenrep Approved by UK MHRA for Multiple Myeloma Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32007#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK’s Blenrep Approved by UK MHRA for Multiple Myeloma Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK's Blenrep Approved by UK MHRA for Multiple Myeloma Treatment - Insight, China's Pharmaceutical Industry","description":"UK-based pharmaceutical giant UK-based pharmaceutical company GlaxoSmithKline (GSK, NYSE: GSK)\u00a0 has announced the receipt of marketing approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin). The approval allows Blenrep to be used in combination with bortezomib plus dexamethasone (BVd) for adults with multiple myeloma (MM) who have received at least one prior therapy, and with pomalidomide plus dexamethasone (BPd) for patients who have received at least one prior therapy including lenalidomide. This marks the first global approval for Blenrep in these specific treatment settings.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32007","og_locale":"en_US","og_type":"article","og_title":"GSK's Blenrep Approved by UK MHRA for Multiple Myeloma Treatment","og_description":"UK-based pharmaceutical giant UK-based pharmaceutical company GlaxoSmithKline (GSK, NYSE: GSK)\u00a0 has announced the receipt of marketing approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin). The approval allows Blenrep to be used in combination with bortezomib plus dexamethasone (BVd) for adults with multiple myeloma (MM) who have received at least one prior therapy, and with pomalidomide plus dexamethasone (BPd) for patients who have received at least one prior therapy including lenalidomide. This marks the first global approval for Blenrep in these specific treatment settings.","og_url":"https:\/\/flcube.com\/?p=32007","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-18T05:35:13+00:00","article_modified_time":"2025-04-18T05:35:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1803.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32007#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32007"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK’s Blenrep Approved by UK MHRA for Multiple Myeloma Treatment","datePublished":"2025-04-18T05:35:13+00:00","dateModified":"2025-04-18T05:35:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32007"},"wordCount":248,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32007#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1803.webp","keywords":["ADC \/ XDC","Cancer","GlaxoSmithKline","GSK","NYSE: GSK","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32007#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32007","url":"https:\/\/flcube.com\/?p=32007","name":"GSK's Blenrep Approved by UK MHRA for Multiple Myeloma Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32007#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32007#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1803.webp","datePublished":"2025-04-18T05:35:13+00:00","dateModified":"2025-04-18T05:35:14+00:00","description":"UK-based pharmaceutical giant UK-based pharmaceutical company GlaxoSmithKline (GSK, NYSE: GSK)\u00a0 has announced the receipt of marketing approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin). The approval allows Blenrep to be used in combination with bortezomib plus dexamethasone (BVd) for adults with multiple myeloma (MM) who have received at least one prior therapy, and with pomalidomide plus dexamethasone (BPd) for patients who have received at least one prior therapy including lenalidomide. This marks the first global approval for Blenrep in these specific treatment settings.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32007#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32007"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32007#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1803.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1803.webp","width":1080,"height":608,"caption":"GSK's Blenrep Approved by UK MHRA for Multiple Myeloma Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32007#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK’s Blenrep Approved by UK MHRA for Multiple Myeloma Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1803.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32007"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32007\/revisions"}],"predecessor-version":[{"id":32009,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32007\/revisions\/32009"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32008"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32007"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32007"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}